SAN FRANCISCO, July 10, 2018 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that results of the mHealth Screening to Prevent Strokes (mSToPS) study, which […]
Tag: AFib
Northwestern Medicine Receives Grant to Lead Research into Atrial Fibrillation and Stroke
CHICAGO, June 29, 2018 /PRNewswire-USNewswire/ — The American Heart Association recently selected Northwestern Medicine as one of six centers to be part of a new, grant-funded national network dedicated to researching and understanding the causes of atrial fibrillation, the most common type of […]
AtriCure and Baheal Group Establish Partnership and China Distribution Agreement
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes […]
ARCA biopharma and Medtronic to Collaborate on Atrial Fibrillation Clinical Trial for GencaroTM
BROOMFIELD, Colo.–(BUSINESS WIRE)–ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc. (NYSE:MDT), a leader in medical technologies to improve the treatment of chronic […]
CardioFocus® Announces European CE Mark Approval Of The Next-Generation HeartLight® Excalibur Balloon™ Designed For The Treatment Of Atrial Fibrillation
MARLBOROUGH, Mass., Sept. 27, 2017 /PRNewswire/ — CardioFocus, Inc. today announced the European CE Mark approval of the HeartLight Excalibur Balloon, a next-generation technology designed for the treatment of atrial fibrillation (AF). The Excalibur Balloon leverages the proven universal balloon design of the company’s FDA-approved HeartLight® Endoscopic Ablation […]
AtriCure Announces U.S. Launch of the AtriClip® PRO•V™ Device
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has launched the AtriClip PRO•V™ Left Atrial Appendage (LAA) Exclusion System in the United States. The new […]
Boca Raton Regional Hospital Using New Technology To Map Irregular Heart Rhythms Non-Invasively
NEWS PROVIDED BY Boca Raton Regional Hospital Aug 01, 2017, 12:24 ET BOCA RATON, Fla., Aug. 1, 2017 /PRNewswire-USNewswire/ — Boca Raton Regional Hospital is the first in Florida and one of only five centers nationally to non-invasively map irregular heartbeats in patients with chronic […]
AtriCure (ATRC) Announces Hiring Of Chief Technology Officer
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has hired Salvatore (Sam) Privitera as its Chief Technology Officer. Mr. Privitera will have responsibility for […]
Clinical Trial to Evaluate Medtronic Cryoablation as First-Line Treatment for Patients With Symptomatic Paroxysmal Atrial Fibrillation
Press Release DUBLIN – July 11, 2017 – Medtronic plc (NYSE: MDT) today announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the safety and effectiveness of performing pulmonary vein isolation (PVI) with the Arctic Front Advance(TM) […]
Medtronic Exclusive Reactive ATP(TM) Therapy Slows Progression of Atrial Fibrillation in Real-World Patient Population
Nsadaq GlobeNewswire DUBLIN and VIENNA – June 18, 2017 – Continuing its leadership in the detection, reduction, and treatment of atrial fibrillation (AF), Medtronic plc (NYSE: MDT) today announced that its Reactive ATP(TM) therapy slows the progression of AF in […]